Volv is a technology company.
Volv has raised $250K across 1 funding round.
Volv has raised $250K in total across 1 funding round.
Volv Global is a Swiss digital health and life-sciences technology company specializing in artificial intelligence (AI) and machine learning solutions to improve healthcare outcomes. It develops AI-driven platforms that analyze large-scale healthcare data, such as electronic health records (EHRs) and claims data, to detect rare, difficult-to-diagnose diseases earlier and more accurately. Volv serves healthcare providers, patients, and payers by enabling earlier diagnosis, better patient stratification, and optimized treatment pathways, addressing critical gaps in healthcare with products like inTrigue for disease detection and inCognita for cognitive disorders[1][2].
Founded in Switzerland, Volv Global emerged from the need to harness AI to tackle complex healthcare challenges, particularly in rare and chronic diseases. The company’s founders and team bring expertise in AI, data science, and healthcare, focusing on transforming population-scale data into actionable insights. Early pivotal moments include strategic partnerships, such as with Scailyte, to combine biomarker discovery with AI-driven patient identification, accelerating rare disease diagnosis[1].
Volv rides the growing trend of AI integration in healthcare, particularly in precision medicine and rare disease diagnostics. The timing is critical as healthcare systems worldwide face increasing pressure to reduce costs, improve diagnostic accuracy, and manage chronic and rare diseases more effectively. Advances in AI and data availability create favorable market conditions for Volv’s solutions. By enabling earlier detection and better patient stratification, Volv influences pharmaceutical development, clinical trials, and healthcare delivery, contributing to a shift toward data-driven, personalized healthcare ecosystems[1][2].
Volv Global is positioned for continued growth as AI adoption in healthcare accelerates. Future trends shaping its journey include expanding AI capabilities in multi-modal data analysis, broader adoption of personalized medicine, and regulatory support for AI-driven diagnostics. Volv’s influence is likely to deepen as it scales its technology and partnerships, potentially becoming a cornerstone in the global effort to close diagnostic gaps and improve patient outcomes in rare and complex diseases. Its commitment to privacy and data ethics will also be a competitive advantage as data governance becomes more stringent[1][2].
Volv has raised $250K in total across 1 funding round.
Volv's investors include Greatscale Ventures.
Volv has raised $250K across 1 funding round. Most recently, it raised $250K Seed in April 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2020 | $250K Seed | Greatscale Ventures |